Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19209435 | COMPOSITIONS AND METHODS FOR TREATMENT | May 2025 | October 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18731209 | REAGENTS, REAGENT KITS, AND CULTURE MEDIA FOR ACTIVATING AND EXPANDING IMMUNE CELLS AND USES THEREOF | May 2024 | May 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18601387 | SYSTEM AND METHOD FOR CONVERTING ADIPOSE DERIVED MESENCHYMAL STEMS CELLS TO HEMATOPOIETIC STEM/PROGENITOR CELLS AND DIFFERENTIATING INTO BLOOD CELLS AND APPLICATIONS OF SAME | March 2024 | March 2026 | Abandon | 24 | 3 | 1 | Yes | No |
| 18414374 | CHEMOPREDICTIVE ASSAY FOR RECURRENT CHEMOTHERAPY | January 2024 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18485458 | ACELLULAR COMPOSITIONS AND METHODS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 17823091 | GENE-EDITED NATURAL KILLER CELLS | August 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17810238 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS | June 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17776860 | RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY ENGINEERED T CELLS TARGETING CD70 | May 2022 | January 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17592019 | METHODS FOR TREATING NON-CANCEROUS DISORDERS USING HEMATOPOIETIC CELLS | February 2022 | September 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17630884 | METHODS OF T CELL PRODUCTION | January 2022 | October 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17608935 | METHODS AND COMPOSITIONS USING AUXOTROPHIC REGULATABLE CELLS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17405735 | CYTOPROTECTIVE COMPOSITIONS FOR SHORT-TERM CELLS STORAGE AND TRANSPORTATION WITHOUT CRYOPRESERVATION AND DEEP FREEZING | August 2021 | June 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17364646 | AUGMENTATION OF NATURAL KILLER CELL ACTIVITY AND INDUCTION OF CYTOTOXIC IMMUNITY USING LEUKOCYTE LYSATE ACTIVATED ALLOGENEIC DENDRITIC CELLS: STEMVACS | June 2021 | March 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17298271 | CHIMERIC ANTIGEN RECEPTOR FACTORIES AND METHODS OF USE THEREOF | May 2021 | July 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17297897 | FOXP1-ABLATED CHIMERIC CELLS | May 2021 | April 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17297052 | ANTI-NEUROPILIN-1 AND ANTI-PROGRAMMED CELL DEATH-1 COMBINATION THERAPY FOR TREATING CANCER | May 2021 | December 2025 | Abandon | 54 | 2 | 0 | No | No |
| 17293835 | METHOD FOR CULTURING CORD BLOOD-DERIVED NATURAL KILLER CELLS USING TRANSFORMED T-CELLS | May 2021 | February 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17281919 | COMPOSITIONS AND METHODS FOR MULTIPLEXED QUANTITATIVE ANALYSIS OF CELL LINEAGES | March 2021 | December 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17269612 | COMBINATION OF NATURAL KILLER CELLS WITH CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER | February 2021 | April 2025 | Abandon | 49 | 2 | 0 | Yes | No |
| 17132103 | METHOD OF OBTAINING A POLYEPITOPIC PROTEIN AND POLYEPITOPIC DNA VECTOR | December 2020 | August 2025 | Abandon | 56 | 2 | 0 | No | No |
| 17253455 | MITOCHONDRIAL AUGMENTATION THERAPY FOR PRIMARY MITOCHONDRIAL DISEASES | December 2020 | September 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 17059509 | EXPANSION AND CULTURE OF HUMAN-DERIVED NATURAL KILLER CELLS BY USING IGFBP2 | November 2020 | October 2025 | Abandon | 59 | 4 | 0 | Yes | No |
| 17094935 | LAYERED BODY | November 2020 | October 2024 | Abandon | 47 | 2 | 1 | Yes | No |
| 17042030 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | September 2020 | August 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 16971016 | CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED-ENDED DNA (CEDNA) VECTORS | August 2020 | March 2026 | Abandon | 60 | 4 | 0 | No | No |
| 16969854 | METHOD FOR GENERATING CELLS OF THE T CELL LINEAGE | August 2020 | March 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 16969278 | GENE THERAPY OF THE FAAH PSEUDOGENE | August 2020 | October 2024 | Allow | 51 | 3 | 0 | Yes | No |
| 16964277 | EXTENDED SINGLE GUIDE RNA AND USE THEREOF | July 2020 | April 2025 | Allow | 57 | 5 | 1 | Yes | No |
| 16962877 | DISRUPTING THE LINC COMPLEX FOR TREATING LAMINOPATHY | July 2020 | March 2025 | Allow | 56 | 4 | 0 | Yes | No |
| 16925174 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | July 2020 | January 2023 | Allow | 30 | 4 | 0 | No | Yes |
| 16770767 | METHODS AND COMPOSITIONS FOR DETECTING AND PROMOTING CARDIOLIPIN REMODELING AND CARDIOMYOCYTE MATURATION AND RELATED METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION | June 2020 | April 2025 | Abandon | 58 | 2 | 2 | No | No |
| 16755453 | Expression Cassette for Production of High-Expression and High-Functionality Target Protein and Use Thereof | April 2020 | September 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16639836 | CHIMERIC ANTIGEN RECEPTORS THAT TARGET MOLECULES ON DISEASE-ASSOCIATED MACROPHAGES AND METHODS RELATED THERERTO, AND TREATMENT OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE CONDITIONS | February 2020 | February 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16732948 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | January 2020 | September 2025 | Abandon | 60 | 4 | 2 | No | No |
| 16706065 | FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS | December 2019 | July 2025 | Abandon | 60 | 2 | 3 | Yes | No |
| 16081340 | 3-D COLLAGEN SCAFFOLD-GENERATED EXOSOMES AND USES THEREOF | August 2018 | March 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16059156 | DELIVERY DEVICE AND USE THEREOF FOR LOADING CELL PLASMA MEMBRANES | August 2018 | December 2024 | Abandon | 60 | 5 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TIWARI, VYOMA SHUBHAM.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TIWARI, VYOMA SHUBHAM works in Art Unit 1634 and has examined 27 patent applications in our dataset. With an allowance rate of 44.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 54 months.
Examiner TIWARI, VYOMA SHUBHAM's allowance rate of 44.4% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TIWARI, VYOMA SHUBHAM receive 2.78 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by TIWARI, VYOMA SHUBHAM is 54 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +65.0% benefit to allowance rate for applications examined by TIWARI, VYOMA SHUBHAM. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 11.1% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 25.0% are granted (fully or in part). This grant rate is in the 13% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.